MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →

Apyx Medical Stock

Apyx Medical Corporation

APYXNASDAQMarkt
US$2.55
-0.4% today

Company data

Sector
Healthcare
Industry
Medical - Specialties
Country
United States
CEO
Charles D. Goodwin
Employees
205
Market cap
$107 M
IPO
02/01/2019

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma…

Apyx Medical stock: price history

16/10/25-18 %16/10/26

1D

-0.4%

1W

-1.5%

1M

-15.3%

6M

-35.9%

YTD

-27.1%

1Y

-18.0%

2Y

+107.3%

5Y

-80.6%

10Y

–

Next earnings date

Next earnings date

05/11/2026 (in 19 days)

Volatility around earnings

~135% stronger price swings than usual

Ask the agents about Apyx Medical

Analyst assessment of Apyx Medical

PRICE TARGET LOW

US$6.00

CONSENSUS

US$6.50

MEDIAN

US$6.50

PRICE TARGET HIGH

US$7.00

0

STRONG BUY

8

BUY

1

HOLD

0

SELL

0

STRONG SELL

9

TOTAL · Buy

As of: 11/03/2026

ANALYST FIRMRATINGACTIONDATE
Craig-HallumBuymaintain11/03/2026
BTIGNeutral → Buyupgrade11/03/2026
CitizensMarket Perform → Market Outperformupgrade12/11/2025
Stephens & Co.Overweightmaintain10/11/2023 (older than 12 months)
Piper SandlerOverweightmaintain11/08/2023 (older than 12 months)
Lake StreetBuymaintain15/06/2023 (older than 12 months)
JMP SecuritiesMarket Perform → Performmaintain24/05/2023 (older than 12 months)
Lake StreetBuymaintain12/05/2023 (older than 12 months)

Apyx Medical stock metrics

P/E

-12.34

P/B

10.08

EV/EBITDA

-74.41

RETURN ON EQUITY

-30.4%

NET MARGIN

-23.4%

DEBT/EQUITY

3.72

DIVIDEND YIELD

0.0%

AS OF

30/06/2026

Free float & liquidity

FREE FLOAT

86.4%

FLOAT SHARES

36,411,059

AVG. DAILY VOLUME (30D)

139,366

Insider transactions (SEC)

ROLETRANSACTIONSHARESPRICEPLAN TYPEDATE

Waldman Lawrence

DirectorOption exercise12,0001.88Spontaneous02/07/2026

Waldman Lawrence

DirectorTax settlement5,0244.49Spontaneous02/07/2026

Roman Shawn David

OfficerOption exercise15,0003.23Spontaneous17/06/2026

Roman Shawn David

OfficerTax settlement10,5334.6Spontaneous17/06/2026

Vizirgianakis Stavros G.

DirectorGrant450,000–Spontaneous15/06/2026

Institutional holders

FUND / INSTITUTIONSHARESCHANGEAS OF
ROYCE & ASSOCIATES LP3,274,064+662,84030/06/2026
Nantahala Capital Management, LLC3,270,248-170,05630/06/2026
Archon Capital Management LLC2,644,717-146,20630/06/2026
VANGUARD CAPITAL MANAGEMENT LLC1,534,847-20,42530/06/2026
ESSEX INVESTMENT MANAGEMENT CO LLC1,136,630+235,23230/06/2026
Page 1 / 3

Comparable stocks

Frequently asked questions about Apyx Medical stock

What does Apyx Medical do?

Apyx Medical Corporation is a company in the Healthcare sector, Medical - Specialties industry, headquartered in United States.

The CEO is Charles D. Goodwin, the company employs around 205 people.

The IPO was on 02/01/2019; the stock trades on NASDAQ under the ticker APYX.

What do analysts say about Apyx Medical stock?

9 analysts rate the stock, the consensus is Buy (as of 11/03/2026).

The average price target is US$6.50, ranging from US$6.00 to US$7.00, with a median of US$6.50.

This is an external assessment, not a statement by Market Jury.

When does Apyx Medical report next?

The next earnings date is 05/11/2026.

Around past earnings, price swings were roughly 135% stronger than usual.

Does Apyx Medical pay a dividend?

No, Apyx Medical currently does not pay a dividend.

Which stocks are comparable to Apyx Medical?

Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Eli Lilly and Company, Johnson & Johnson and AbbVie.

How can I get Apyx Medical stock analyzed?

Clicking "Analyze stock" lets five strategies assess Apyx Medical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.